Q-omics provides the consensus-scored FCGR3B profile across patient tissues and cancer cell-line models. FCGR3B expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, FCGR3B is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, FCGR3B RNA expression shows 20,526 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight UVM, KIRC, and PDAC as cancer lineages where FCGR3B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FCGR3B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FCGR3B survival associations across molecular data types. FCGR3B RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FCGR3B RNA expression–survival associations across cancer types. High FCGR3B expression shows unfavorable associations in UVM, KICH, ESCA and LGG, but favorable associations in UCEC and COAD. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UVM as the clearest survival context for FCGR3B RNA expression.
This table summarizes FCGR3B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 4. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for FCGR3B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FCGR3B shows lower tumor expression in LUAD, LUSC, LIHC and THCA and higher tumor expression in KIRC and ESCA. The KIRC box plot shows higher FCGR3B RNA expression in tumor versus normal tissue (log2 FC = +1.005, t-test p < 0.001).
This table shows molecular features associated with FCGR3B in patient tissues and cancer cell lines. In patient samples, FCGR3B shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, FCGR3B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in BONE and BREAST.
